On Tuesday, United Continental Holdings Inc (NYSE:UAL)’s shares inclined 0.38% to $53.01.
United Airlines declared an historic $30 million equity investment in U.S.-based alternative fuels developer Fulcrum BioEnergy, Inc., a pioneer in the development and commercialization of converting municipal solid waste into low-cost sustainable aviation biofuel. It is also the single largest investment by a U.S. airline in alternative fuels and sets United apart in the aviation industry in the advancement of aviation biofuels and carbon emissions reductions. In addition to the equity investment, United and Fulcrum have reached a contract that contemplates the joint development of up to five projects located near United’s hubs predictable to have the potential to produce up to 180 million gallons of fuel per year.
United Continental Holdings, Inc., together with its auxiliaries, provides air transportation services in North America, the Asia-Pacific, Europe, the Middle East, Africa, and Latin America. It transports people and cargo through its mainline operations, which use jet aircraft with at least 118 seats, and its regional operations. As of December 31, 2014, the company operated a fleet of 1,257 aircraft. It also sells fuel; and provides maintenance, ground handling, and catering services for third parties.
Novavax, Inc. (NASDAQ:NVAX)’s shares gained 5.49% to $11.14.
Novavax, Inc. (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared the appointment of Gail K. Boudreaux to its Board of Directors.
Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience comprises more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is presently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline comprises respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, in addition to pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, in addition to rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial.
At the end of Tuesday’s trade, Dow Chemical Co (NYSE:DOW)‘s shares surged 0.75% to $51.17.
Scientists from The Dow Chemical Company (DOW) who led the development of INSITE™ catalyst, a revolutionary technology that made possible highly-tailored materials bridging the properties of plastic and rubber, recently were named among the 2015 “Heroes of Chemistry,” a prestigious award given by the American Chemical Society (ACS).
Polymer brands ENGAGE™ Polyolefin Elastomers, NORDEL™ EPDM and AFFINITY™ Polyolefin Elastomers from Dow, used in many of recently’s growing consumer markets, counting automotive, building and construction and consumer packaging, have been made possible by the breakthrough catalyst technology of INSITE™. These and other new-to-the-world polymer families derived from INSITE™ continue to revolutionize the plastics industry.
Scientists involved in the INSITE™ project comprise David Devore, Morris Edmondson, Pradeep Jain, George Knight, Brian Kolthammer, Shih-Yaw Law, Robert LaPointe, David Neithamer, Peter Nickias, Jasson Patton, Robert Rosen, James Stevens, Francis Timmers, Daniel VanderLende and David Wilson. Collectively, Dow’s research and development engine was responsible for more than 635 U.S. patents granted in 2014 — surpassing the previous year’s all-time record by more than 10 percent.
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments. The Agricultural Sciences segment provides crop protection and seed/plant biotechnology products and technologies, urban pest administration solutions and healthy oils, insecticides, fungicides, herbicides, and seeds.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ended its Tuesday’s trading session with 5.87% gain, and closed at $8.30.
Synergy Pharmaceuticals Inc. (SGYP) declared that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 at 2:30 p.m. Eastern Time at Le Parker Meridien Hotel in New York City.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
